Participants who were prescribed celecoxib at baseline per treating physician's judgment. Participants could switch to nonselective non-steroidal anti-inflammatory drugs (nsNSAIDs) at any time during the study. The use and dosage recommendations for celecoxib took place on the basis of the approved Product Label and were adjusted solely according to medical and therapeutic necessity.

Participants who were prescribed nsNSAIDs at baseline per treating physician's judgment. Any nsNSAID could be used at the discretion of the investigator, provided that the medicine was not contraindicated for the participant as per the current United States product information for that nsNSAID. Participants could switch to other nsNSAIDs or celecoxib at any time during the study. The use and dosage recommendations for study drug took place on the basis of the approved Product Label and were adjusted solely according to medical and therapeutic necessity.

Total of all reporting groups

Number of participants with JIA by subtype: systemic persistent oligoarticular, extended oligoarticular, polyarticular rheumatoid factor negative (Poly RF-) and positive (Poly RF+).

Participant or caregiver reported severity of participant's stomach problems during the last week using visual analogue scale (VAS), scores ranged from 0 (no trouble at all) to 100 (severe stomach problems). Also identified types of participant's stomach problems, if any, during the last week by selecting one or more check boxes.

JIA medications by class: GI protective agents (eg, proton-pump inhibitors), other GI, DMARDs, biologics, antihypertensives, NSAIDs (Celecoxib, Diclofenac, Ibuprofen, Meloxicam, Naproxen, other), corticosteroids (oral, intravenous [IV], intra-articular, other forms), analgesics (eg, Acetaminophen). Participants could receive more than 1 medication.

Abnormal findings in physical examination as determined by physician

PGA measured on a scale from 0 (not active) to 10 (very active) where higher scores indicated more disease activity.

Overall well being measured on a scale from 0 (very well) to 10 (very poor).

CHAQ: validated parent or legal guardian assessed instrument of child's activities of daily living, pain, and global assessment. Global evaluation rated on a visual analog scale (VAS) from 0 (very well) to 100 (very poor) where higher scores indicated a worse evaluation.

CHAQ: validated parent or legal guardian assessed instrument of child's activities of daily living, pain, and global assessment. Pain rated on a VAS from 0 (no pain) to 100 (severe pain). Scores converted to 0, 1, 2, or 3 where 0 = no pain and 3 = severe pain.

Daily functioning included questions on level of difficulty child had with 8 categories of daily living. Responses ranged from 'without any difficulty' (0) to 'unable to do' (3). Functioning score = sum of highest score in each category divided by number of categories answered; scores ranged from 0 to 3; higher scores indicated more impairment.

Active arthritis defined as swelling or limitation of motion of the joint accompanied by heat, pain, or tenderness. A total of 36 joints and spine (cervical, thoracic, and lumbar) checked.

GISSK is a validated measure of GI symptom severity and types of GI problems, if any. For severity of stomach problems, participant or caregiver reported severity of participant's stomach problems during the last week using VAS, where scores ranged from 0 (no trouble at all) to 100 (severe stomach problems).

Based on World Health Organization (WHO) 2000 Centers for Disease Control growth charts. BMI = Weight in Kilograms divided by (/) (Height in Meters multipled by [*] Height in Meters).

Percentile category based on WHO 2000 Centers for Disease Control growth charts

Participants who were prescribed celecoxib at any time during the study. Treatment assignment per treating physician's judgment. The use and dosage recommendations for celecoxib took place on the basis of the approved Product Label and were adjusted solely according to medical and therapeutic necessity.

Participants who received nsNSAIDs at any time during the study. Treatment assignment per treating physician's judgment. The use and dosage recommendations for nsNSAIDs took place on the basis of the approved Product Label and were adjusted solely according to medical and therapeutic necessity.